Anthony K Hall
Research Subjects
Research Interests
Anthony K Hall has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth Ludington
Agility Clinical, Carlsbad, CA, USA
1 shared publicationMarilyn R Carlson
Agility Clinical, Carlsbad, CA, USA
1 shared publication
Latest Publications
- 1 January 2014
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 3 (1) , 1-7
The current status of orphan drug development in Europe and the US
Orphan drug legislation has been introduced in a number of countries in order to stimulate the development of treatments for rare diseases by introducing commercial incentives for companies wishing to undertake that development. In order to navigate the maze of regulatory regulations and procedures so that companies can make proper use of the orphan drug incentives, specialist knowledge is required. This article will review the current status of orphan drug development in the EU and the US, explain the incentives and procedures, and touch on the role of patient organisations in the process.
- 1 January 2014
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 3 (1) , 1-7
The current status of orphan drug development in Europe and the US
Orphan drug legislation has been introduced in a number of countries in order to stimulate the development of treatments for rare diseases by introducing commercial incentives for companies wishing to undertake that development. In order to navigate the maze of regulatory regulations and procedures so that companies can make proper use of the orphan drug incentives, specialist knowledge is required. This article will review the current status of orphan drug development in the EU and the US, explain the incentives and procedures, and touch on the role of patient organisations in the process.
- Open Access
- 14 October 2013
- Published by Informa Healthcare in Expert Opinion on Orphan Drugs
- Vol. 1 (11) , 847-850
Considerations for successful clinical development for orphan indications
Clinical trials (programs) for orphan indications present unique challenges for the drug developer. The fact that the disease is often poorly characterised and under-researched makes it difficult to define suitable clinical parameters; the paucity of patients and specialist centres create logistical issues; the fact that the regulatory framework is not always well suited to novel therapies in a small and unstudied patient group requires innovative thinking and interaction with the regulators to achieve an appropriate study design. These factors all need to be given adequate consideration when developing treatments for orphan indications.
- 14 October 2013
- Published by Informa Healthcare in Expert Opinion on Orphan Drugs
- Vol. 1 (11) , 847-850
Open AccessConsiderations for successful clinical development for orphan indications
Clinical trials (programs) for orphan indications present unique challenges for the drug developer. The fact that the disease is often poorly characterised and under-researched makes it difficult to define suitable clinical parameters; the paucity of patients and specialist centres create logistical issues; the fact that the regulatory framework is not always well suited to novel therapies in a small and unstudied patient group requires innovative thinking and interaction with the regulators to achieve an appropriate study design. These factors all need to be given adequate consideration when developing treatments for orphan indications.